The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
==== Hydrodynamic countercurrent chromatography (CCC) ==== The operating principle of CCC instrument requires a column consisting of an open tube coiled around a bobbin. The bobbin is rotated in a double-axis gyratory motion (a cardioid), which causes a variable gravity (G) field to act on the column during each rotation. This motion causes the column to see one partitioning step per revolution and components of the sample separate in the column due to their partitioning coefficient between the two immiscible liquid phases used. There are many types of CCC available today. These include HSCCC (High Speed CCC) and HPCCC (High Performance CCC). HPCCC is the latest and best-performing version of the instrumentation available currently.
17α-Alkylation: methyltestosterone, metandienone, fluoxymesterone, oxandrolone, oxymetholone, stanozolol, norethandrolone, ethylestrenol 19-Demethylation: nandrolone, trenbolone, norethandrolone, ethylestrenol, trestolone, dimethandrolone 5α-Reduction: androstanolone, drostanolone, mestanolone, mesterolone, metenolone, oxandrolone, oxymetholone, stanozolol 3β- and/or 17β-esterification: testosterone enanthate, nandrolone decanoate, drostanolone propionate, boldenone undecylenate, trenbolone acetate As well as others such as 1-dehydrogenation (e.g., metandienone, boldenone), 1-substitution (e.g., mesterolone, metenolone), 2-substitution (e.g., drostanolone, oxymetholone, stanozolol), 4-substitution (e.g., clostebol, oxabolone), and various other modifications.
== Biography == In 1993, he immigrated to Canada. Prior to the formation of DVS Sciences. Dr. Baranov, a senior scientist at MDS SCIEX, was a key member of the research team that developed and promoted the Dynamic Reaction Cell®, which remains today at the pinnacle of quadrupole ICP-MS technology. In 2005, together with Scott D. Tanner and Dmitry Bandura, he began independently developing an ICP-TOF-MS based cytometer and became a researcher at the University of Toronto in March 2005. After securing ample funding by 2010 from various sources, including National Institutes of Health, Ontario Institute for Cancer Research (OICR), the Ministry of Research and Innovation, Ontario Centres of Excellence, Health Technology Exchange, and Genome Canada via the Ontario Genomics Institute, and venture capital from 5 AM Ventures, Vladimir and the DVS Sciences team successfully commercialized their technology, leading to the acquisition of DVS Sciences by Fluidigm in 2014 Baranov was a principal scientist at DVS Sciences (and then Fluidigm) developing instrumental concepts and algorithmics that advance the CyTOF® line of products. He also and played a fundamental role in the development of the MaxPar line of metal-labeling reagents until his retirement in 2019.
=== Setup of experiments === Cold fusion setups utilize an input power source (to ostensibly provide activation energy), a platinum group electrode, a deuterium or hydrogen source, a calorimeter, and, at times, detectors to look for byproducts such as helium or neutrons. Critics have variously taken issue with each of these aspects and have asserted that there has not yet been a consistent reproduction of claimed cold fusion results in either energy output or byproducts. Some cold fusion researchers who claim that they can consistently measure an excess heat effect have argued that the apparent lack of reproducibility might be attributable to a lack of quality control in the electrode metal or the amount of hydrogen or deuterium loaded in the system. Critics have further taken issue with what they describe as mistakes or errors of interpretation that cold fusion researchers have made in calorimetry analyses and energy budgets.
The rise of field guides for the identification of birds was another major innovation. The early guides such as Thomas Bewick's two-volume guide and William Yarrell's three-volume guide were cumbersome, and mainly focused on identifying specimens in the hand. The earliest of the new generation of field guides was prepared by Florence Merriam, sister of Clinton Hart Merriam, the mammalogist. This was published in 1887 in a series Hints to Audubon Workers: Fifty Birds and How to Know Them in Grinnell's Audubon Magazine. These were followed by new field guides, from the pioneering illustrated handbooks of Frank Chapman to the classic Field Guide to the Birds by Roger Tory Peterson in 1934, to Birds of the West Indies published in 1936 by Dr. James Bond - the same who inspired the amateur ornithologist Ian Fleming in naming his famous literary spy. The interest in birdwatching grew in popularity in many parts of the world, and the possibility for amateurs to contribute to biological studies was soon realized. As early as 1916, Julian Huxley wrote a two-part article in The Auk, noting the tensions between amateurs and professionals, and suggested the possibility that the "vast army of bird lovers and bird watchers could begin providing the data scientists needed to address the fundamental problems of biology." The amateur ornithologist Harold F. Mayfield noted that the field was also funded by non-professionals. He noted that in 1975, 12% of the papers in American ornithology journals were written by persons who were not employed in biology related work.
Sources: en.wikipedia.org
=== Appointments === After U.S. Senator Kamala Harris was elected vice president of the United States in the 2020 U.S. presidential election, Newsom appointed Secretary of State of California Alex Padilla to succeed her as California's junior U.S. senator. To replace Padilla as secretary of state, Newsom appointed Assemblywoman Shirley Weber. After the U.S. Senate confirmed Xavier Becerra as U.S. Secretary of Health and Human Services, Newsom appointed Rob Bonta Attorney General of California. In an interview with Joy Reid, Newsom was asked whether he would appoint a Black woman to replace Dianne Feinstein if she were to retire from the Senate or die before her term ended in 2024; Newsom replied that he would. Feinstein died in September 2023, and Newsom faced pressure to quickly appoint a successor. He fulfilled his promise and appointed Laphonza Butler to the seat.
SNAP-tag® is a self-labeling protein tag commercially available in various expression vectors. SNAP-tag is a 182 residue polypeptide (19.4 kDa) that can be fused to any protein of interest and further specifically and covalently tagged with a suitable ligand, such as a fluorescent dye. Since its introduction, SNAP-tag has found numerous applications in biochemistry and for the investigation of the function and localisation of proteins and enzymes in living cells.
Xylazine is a structural analog of clonidine and an α2-adrenergic receptor agonist, sold under many trade names worldwide, most notably the Bayer brand name Rompun, as well as Anased, Sedazine and Chanazine. Xylazine is a common veterinary drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals such as horses, cattle, and other mammals. In veterinary anesthesia, it is often used in combination with ketamine. Veterinarians also use xylazine as an emetic, especially in cats. Drug interactions vary with different animals. Xylazine was first investigated for human use in the 1960s in West Germany for antihypertensive effects before being discontinued and marketed as a veterinary sedative. Xylazine's mechanism of action was discovered in 1981, which led to the creation of other α2-adrenergic receptor agonists such as medetomidine and dexmedetomidine. Xylazine has become a commonly abused street drug in the United States where it is known by the street name "tranq", particularly in the territory of Puerto Rico. The drug is used as a cutting agent for heroin and fentanyl.
Chair of Trustees, Molly Rose Foundation. For services to Child Safety Online. Martin Henry Charles Russell, DL. For services to the community in the London Borough of Barnet. Rosemary Priscilla Irene Russell. Art and Design and Technology Technician, The Ursuline Academy Ilford. For services to Education and to Diversity in STEM. Elizabeth Joan Ryan. Lately Volunteer, Luton, South Bedfordshire and Harpenden Samaritans. For services to Suicide Prevention. Sadia Sadiq. Manager, Community Care and Wellbeing Services. For services to Minority Ethnic Communities in Wales. Lorraine Sanda. Strategic Director of People, Clackmannanshire Council. For services to Children and Families. Carolene Euleata Sargeant (Carolene Hinds). Independent Performing Arts Professional. For services to Dance. Professor William Peter Saunders. Chief Creative Officer, StoryFutures at Royal Holloway University. For services to the Creative Industries. Alison Melanie Savage. Officer Commanding, The Services Cotswold Centre. For services to Military Families. Jacqueline Savage. Volunteer. For services to Social Care. Majida Aly Sayam. Founder and Director, Jannaty Women's Social Society. For charitable services to Ethnic Minority Women. Kimberley Louise Scott. Lately Assistant Director of Education, Education Authority. For services to Education. Jacqueline Scrivens (Jacqueline Forester). Proprietor, The Woodshed Forest School Nursery. For services to Early Years Child-Lead Learning. Josephine Patricia Segal. Co-Founder, Spread a Smile.
Sources: en.wikipedia.org
A&W Restaurants entered the Canadian market in 1956. In 1972, the American company sold the Canadian unit to Unilever thus creating A&W (Canada). In 1995, it was spun off into an independent entity with no ties to its American counterpart. They have over 800 locations nationwide.
In 1998 the BPL began sourcing its plasma from the United States due to concerns over vCJD in the UK. In 2002 the Department of Health (DoH) formed DCI Biologicals Inc to purchase US company Life Resources Inc to supply all of the BPL's plasma. BPL became an operating division within new special health authority, NHS Blood and Transplant, in 2005. This placed BPL alongside the National Blood Service and the organ transplant division, a strategic partnership to safeguard blood, tissues and blood products. On 31 December 2010 the BPL was vested into a limited company, Bio Products Laboratory Ltd, and ownership transferred to the DoH, with BPL Ltd and DCI Biologicals Inc brought under the same DoH holding company, Plasma Resources UK Ltd. On 18 July 2013 it was announced by Business Secretary Vince Cable that Bain Capital had bought 80% of Plasma Resources UK (PRUK) from the DoH for £230m, which included both BPL and DCI Biologicals. The company was subsequently renamed BPL Holdings, with the original BPL site now called BPL Therapeutics and DCI named BPL Plasma. In 2018, when it was the sole owner, the Chinese group Creat had announced that it planned to integrate BPL's operations with German plasma product manufacturer Biotest. In 2022, Creat was required to dispose of its U.S. plasma centers which necessitated a sale of BPL as a whole. The sale was made to Kedrion BioPharma and BPL became a subsidiary of the Kedrion Group.
The International Diabetes Federation estimates nearly 537 million people lived with diabetes worldwide in 2021, 90–95% of whom have type 2 diabetes. Diabetes is common both in the developed and the developing world. Some ethnic groups such as South Asians, Pacific Islanders, Latinos, and Native Americans are at particularly high risk of developing type 2 diabetes. Type 2 diabetes in normal weight individuals represents 60 to 80 percent of all cases in some Asian countries. The mechanism causing diabetes in non-obese individuals is poorly understood. Rates of diabetes in 1985 were estimated at 30 million, increasing to 135 million in 1995 and 217 million in 2005. This increase is believed to be primarily due to the global population aging, a decrease in exercise, and increasing rates of obesity. Traditionally considered a disease of adults, type 2 diabetes is increasingly diagnosed in children in parallel with rising obesity rates. The five countries with the greatest number of people with diabetes as of 2000 are India having 31.7 million, China 20.8 million, the United States 17.7 million, Indonesia 8.4 million, and Japan 6.8 million. It is recognized as a global epidemic by the World Health Organization.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.